Shots:

• The NICE approval is based on P-III MONALEESA-3 study results assessing Kisqali + fulvestrant vs fulvestrant as monothx. in patients with HR+/HER2- LA or metastatic breast cancer prior treated with endocrinal therapy
• The P-III MONALEESA-3 study results: mPFS (20.5 mos. vs 12.8 mos.); 2L post-menopausal patients- mPFS (14.6 mos. vs 9.1 mos.)
• Kisqali is a CDK4/6 inhibitor and is an approved therapy in the US and EU for breast cancer- will be available on the Cancer Drugs Fund (CDF) following its approval by NICE published in the draft guidance

Ref: NICE | Image: The Business Journals